New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
04:55 EDTALSO, ALSO, ALSO, ABIO, ABIO, ABIO, MILL, MILL, MILL, PBIO, PBIO, PBIO, VLDI, VLDI, VLDI, CCGI, CCGI, CCGI, FNRG, FNRG, FNRG, SCIE, SCIE, SCIE, BIOL, BIOL, BIOLSNN and Growth Capital Investor to hold an expo
Growth Capital Expo is being held in Las Vegas on April 29-May 1.
News For ALSO;ABIO;MILL;PBIO;VLDI;CCGI;FNRG;SCIE;BIOL From The Last 14 Days
Check below for free stories on ALSO;ABIO;MILL;PBIO;VLDI;CCGI;FNRG;SCIE;BIOL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
17:31 EDTBIOLBIOLASE files to sell 6.25M shares of common stock for holders
08:17 EDTMILLMiller Energy receives $31.2M tax credit certificate
Subscribe for More Information
August 20, 2014
13:02 EDTSCIESpectrascience to host business news update conference call
Conference call to provide a business news update will be held on August 26 at 4:30 pm. Webcast Link
08:21 EDTMILLMiller Energy increases total proved reserves from $361M to $448M
Miller Energy announced a substantial increase in the estimated value of its reserves located in the Cook Inlet area of Alaska in a recently issued reserve report commissioned by the company. Total proved PV-10 increased from $360.9M at April 30 to $447.6M at July 31. Miller CEO Scott M. Boruff stated, "This increase demonstrates reserve growth in our Alaskan assets, including Redoubt, West McArthur River and North Fork. As we prove up additional fault blocks at Redoubt and begin drilling out our promising Sabre prospect, we expect further meaningful additions to our reserves, as well as strong increases in production."
August 19, 2014
15:54 EDTMILLEnerCom to hold a conference
Subscribe for More Information
August 18, 2014
08:34 EDTABIOARCA Biopharma announces GENETIC-AF CTA accepted by Health Canada
ARCA biopharma announced that the company’s Clinical Trial Application for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in Q4. ARCA is evaluating Gencaro as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the U.S. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically targeted therapy for the prevention of atrial fibrillation.
August 14, 2014
08:47 EDTMILLMiller Energy acquires Anchor Point Energy
Subscribe for More Information
August 11, 2014
08:27 EDTMILLMiller Energy to acquire exploration license on 168K acres in Cook Inlet
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use